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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the
coronavirus disease (COVID-19), is a contagion that has rapidly spread around the
globe. COVID-19 has caused significant loss of life and disrupted global society at a
level never before encountered. While the disease was predominantly characterized
by respiratory symptoms initially, it became clear that other systems including the
cardiovascular and neurological systems were also involved. Several thrombotic
complications were reported including venous thrombosis, vasculitis, cardiomyopathy,
and stroke. Thrombosis and inflammation are implicated in various non-communicable
diseases (NCDs). This is of significant concern as people with pre-existing conditions
such as cardiovascular disorders, renal disorders, obesity, metabolic syndrome, and
diabetes are at greater risk of severe COVID-19 infection. Consequently, the research
surrounding the use of anticoagulants, antiplatelet, and antithrombotic strategies for
prophylaxis and treatment of COVID-19 is of critical importance. The adoption of a healthy
diet, physical exercise, and lifestyle choices can reduce the risk factors associated with
NCDs and the thrombo-inflammatory complications. In this review, these thrombotic
complications and potential foods, nutraceuticals, and the antithrombotic constituents
within that may prevent the onset of severe thrombotic complications as a result of
infection are discussed.While nutrition is not a panacea to tackle COVID-19, it is apparent
that a patient’s nutritional status may affect patient outcomes. Further intensive research
is warranted to reduce to incidence of thrombotic complications.
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INTRODUCTION
Since December 2019, the coronavirus disease (COVID-19) has rapidly spread worldwide
becoming a pandemic as declared by theWorld Health Organization (WHO). Over 20million cases
of COVID-19 have been reported, which is responsible for 738,000 deaths globally as of August
11th (1). COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), which is an enveloped positive-sense single-stranded RNA virus infecting cells of the respiratory
system via the angiotensin-converting enzyme 2 (ACE2) receptor, when the spike protein is primed
by transmembrane protease serine 2 protein (TMPRSS2) (2). SARS-CoV-2 entry into host cells is
followed by a subsequent response of the immune system, which includes inflammation-related
manifestations leading to disproportionate endothelial damage and dysfunction, dysregulation
of perfusion, and a loss of hypoxic vasoconstriction (3). The lungs seem to be the initial target
organ of SARS-CoV-2, whereby patients develop acute lung injury that can progress to respiratory
failure. Symptoms present as upper and lower respiratory tract infections that in severe cases
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is accompanied with inflammatory complications that are
attributed to a cytokine storm and hyperinflammation (4).
The cytokine storm can result in acute respiratory distress
syndrome (ARDS) and potentially multiorgan failure (5, 6).
Infection of the respiratory epithelium is the portal of entry,
whereby alveolar damage may be mediated by endothelial
injury, resulting in the release of cytokines and chemokines, the
recruitment of immune cells, and the activation of coagulation
and thrombosis (6–11). The intense cytokine storm is also
implicated in the virus-triggered pulmonary tissue damage,
functional impairment, reduced lung capacity, and respiratory
failure in severe COVID-19 cases. SARS-CoV-2 may extend to
other organs as documented by reports that patients with severe
COVID-19 often develop neurological issues and multiorgan
damage including cardiac injury and acute kidney injury (6,
7, 12). Indeed, it is now known that other complications such
as hypercoagulability, venous thrombosis, systemic vasculitis,
and stroke are associated with increased mortality in COVID-
19 patients (12, 13). Therefore, identifying, repurposing or
designing therapeutics and preventative strategies to reduce
the risk of thrombotic complications in COVID-19 is of
significant importance.
Currently, there are no known effective prophylactic
treatments for COVID-19 and only limited effectiveness
reported for various therapeutics such as Remdesivir, which
reduces the time to recovery in hospitalized COVID-19 patients
(14). Press releases and preprints occasionally have shed light
on effective treatments such as dexamethasone (15), but many
other potential therapeutics that have come to light have yet to
be peer reviewed and require much further study. Likewise, the
effectiveness of antithrombotic and anticoagulant treatments
is still under investigation. In this mini review, the evidence
surrounding thrombosis and how nutrition may play a role in
the primordial prevention of the development of thrombotic
complications in SARS-CoV-2 infected patients is discussed.
Several nutrients that exhibit antiplatelet activity are summarized
and future directions of nutrition research as a strategy to reduce




Non-communicable diseases (NCDs) seem to be associated
with higher incidences of severe COVID-19 infections (7,
16, 17). This is due to the presence of comorbidities and
risk factors amongst these subpopulations who may be obese,
elderly, or immunocompromised (7, 18). Many NCDs are
associated with thrombotic complications such as cardiovascular
diseases (CVD), acute coronary syndromes, ischemic stroke, deep
vein thrombosis, venous thromboembolism, and pulmonary
embolism (19, 20). While thrombosis is a complication of
COVID-19 (13), the presence of NCDs such as diabetes or obesity
may further increase the risk of thrombotic complications in
severely ill patients due to their associations with a prothrombotic
state (21). Generally, the hemostatic system that is comprised
of coagulation, platelet aggregation, and fibrinolysis, is a host
defense mechanism that maintains the integrity of the circulatory
system following vascular damage (19, 22). The coagulatory and
inflammatory processes are highly regulated and are crucial to
the host defense systems for limiting tissue injury, removing
pathogens, and re-establishing homeostasis (10, 22).
Pulmonary embolism and thrombosis are now known
to contribute to adverse events and increased mortality
in critically ill COVID-19 patients due hypercoagulability
and a prothrombotic state that can lead to coagulopathy
and disseminated intravascular coagulation (11). Therefore,
widespread pulmonary and endothelial inflammation and
enhanced thrombosis are integral features of COVID-19
pathology. This state of hypercoagulation contributes to a fatal
deterioration of the ventilation/perfusion ratio (V/Q), which is
a measure of the concentration of air reaching the alveoli per
minute to the amount of blood reaching the alveoli per minute
via the capillaries (8). This is of clinical importance as hypoxia
and sepsis can independently promote platelet aggregation
mediated by the release of von Willebrand factor, which is
increased in the whole blood of intensive care unit (ICU) patients
with COVID-19 (8, 23). However, further study is required as
only a limited number of patients were enrolled in this study.
The substantial coagulation activation in severe COVID-19
infection is likely related to the sustained inflammatory response
due to the intense cytokine release induced by virus invasion.
Increased levels of D-dimers, a prolongation of prothrombin
time (PT), activated partial thromboplastin time (aPTT), and
thrombocytopenia is representative of disease severity and have
been correlated with poor prognosis and increased mortality in
COVID-19 patients (11, 24). However, whether the hemostatic
changes observed are specific to COVID-19 or are a reflection
of the cytokine storm and systemic inflammation is still subject
to debate. Nevertheless, these changes in hemostatic factors
seems to resemble that of inflammatory markers including IL-
6, which potentially indicates a severe inflammatory response
accompanied by a secondary hypercoagulable state (10, 24).
Indeed, the loss of normal antiplatelet and anti-inflammatory
functions of endothelial cells also leads to dysregulation of
platelet activation, coagulation, and leukocyte recruitment in the
microvasculature, with complement activation possibly playing
an important role in the context of COVID-19-associated
pneumonitis and purpuric skin lesions (6, 24).
Proteomic and metabolomic characterization of COVID-19
patient sera compared to control groups revealed molecular
changes in COVID-19 patients demonstrating dysregulation
of macrophages, evidence of platelet degranulation, the
involvement of complement system pathways, and significant
metabolic suppression, which may be useful as potential
blood biomarkers for disease severity evaluation (25). Vascular
inflammation and viral endotheliitis are frequent in severe
COVID-19 patients as a result of endothelial dysfunction. Large
increases of von Willebrand factor (VWF) and factor VIII
activity has also been observed in COVID-19, which is also
attributed to endothelial damage (26, 27). Notably, even in the
absence of severe disease, patients with COVID-19 may be at
heightened risk of thrombus formation leading to stroke due to
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viral interaction with the endothelium (28). It was reported in
New York City that some patients experiencing mild symptoms
presented with stroke and large vessel thrombosis without
occlusion. Whereas, severely infected patients presented with
venous thrombosis and microangiopathy (28, 29).
In general, viral infections can activate monocytes, tissue
macrophages, and endothelial cells, thus triggering the
production of proinflammatory cytokines and activation
of the coagulation cascade. Inflammation and coagulation
synchronously respond to invading pathogens as part of
the host’s defense system, which includes complex processes
referred to as thrombo-inflammation or immunothrombosis.
In this capacity platelets can become activated following
antigen recognition. Activated platelets can directly gather
and inactivate pathogens and/or facilitate the clearance of
pathogenic microorganisms by promoting the formation of
neutrophil extracellular traps (NETs), activating neutrophils and
macrophages, and facilitating the formation of platelet aggregates
and microthrombi (30), all of which contribute to the crosstalk
between the inflammation and coagulation pathways (7).
The complement system is part of the innate immune system
and represents one of the first responses of the host immune
system to SARS-CoV-2 infection via activation of multiple
pathways (31). As a result of complement activation, there is
significant platelet activation, thrombus formation, endothelial
dysfunction, and intravascular coagulation, that can culminate in
multiorgan failure and death in severe COVID-19 infection (6).
It is hypothesized that C5a and C5b-9 that are generated by cells
infected with SARS-CoV-2 may be key mediators of COVID-
19-associated endothelial dysfunction and platelet activation.
Activation of these cells may lead to the exocytosis of P-selectin
and vonWillebrand factor multimers and the expression of tissue
factor and adhesion molecules from endothelial cells, and the
release of chemokines and platelet-activating factor (PAF), which
together promote inflammation, increase vascular permeability,
and trigger the coagulation process (6, 32). C5b−9 can also be
a powerful platelet agonist by inducing the secretion of storage
granules and the release of procoagulant platelet microparticles
leading to vascular injury and dysfunction followed by the
formation of significant blood clots (6, 32).
Overall, COVID-19 patients have a higher risk for
thromboembolic complications and a higher frequency is
observed in severely ill patients, which can lead to significant
damage (33). As a result, thrombotic complications are a
potential target for the reduction of disease severity.
MITIGATION OF COVID-19 THROMBOTIC
COMPLICATIONS
To avoid thrombotic complications, many have recommended
prophylactic antithrombotic pharmacological therapies for
COVID-19 patients, along with particular dosing instructions
(34–37). However, to date, little research has been conducted
and the optimal doses of anticoagulants or antiplatelet agents has
yet to be determined. Indeed, data for prospective efficacy and
safety of existing antiplatelet therapies to treat or prevent severe
symptoms of COVID-19 remains elusive. Despite that, some
institutes have adopted pharmacological thromboprophylactic
strategies (38). These include the use of intermediate or full-dose
preemptive anticoagulation therapy rather than prophylactic
dosing for routine care of COVID-19 patients (13). Considering
some studies have observed high bleeding rates as a result
of standard anticoagulation treatment in COVID-19 patients,
randomized trials are required to determine any potential
benefit of intensified anticoagulant prophylaxis in COVID-19
patients (39).
One potential therapeutic avenue has shown that antiplatelet
treatments can improve hypoxemia in severe COVID-19 patients
with hypercoagulability by affecting the ventilation/perfusion
ratio in patients with severe respiratory failure (8). However,
antiplatelet and anticoagulant therapies administered pre-
admission to hospital does not seem to protect with ARDS
at presentation who are at significant risk of death (35).
Pharmacological agents targeting thrombo-inflammation in
COVID-19, including antiplatelet compounds, along with
proposed best practices and clinical guidance, has been
extensively reviewed elsewhere (34, 36, 37). In brief, current
guidelines proposed by the International Society of Thrombosis
and Hemostasis recommend low-molecular weight heparin
for both mild and severely infected patients who required
hospitalization (40). However, further guidance for the utilization
of antithrombotic and antiplatelet therapies in patients with
known or suspected COVID-19 are necessary, particularly for
patients with comorbidities (36).
FOODS AND NUTRIENTS WITH
ANTITHROMBOTIC PROPERTIES
Diet and lifestyle are modifiable risk factors that can have a
significant impact on an individual’s likelihood to develop an
NCD (41, 42) and their susceptibility to developing infections
(7). It has previously been described how inflammation and
thrombosis are implicated in the onset and progression of NCDs
(19, 41). However, it has become apparent that one’s nutritional
status is an important factor for priming the immune system to
tackle acute infections such as COVID-19 (7, 43–45). Adoption
of healthy dietary habits will prevent the onset of NCDs, which
is a significant risk factor for the development of COVID-19,
and may provide support to the immune system to lessen the
severity of an infection (7). A healthy diet in compliance with
current nutritional recommendations can lead to less societal
and economic burden to health systems and economies (7, 46).
Therefore, promotion of a healthy diet and lifestyle among
the general population characterized by anti-inflammatory and
antithrombotic properties may potentially benefit or prevent the
thrombo-inflammatory manifestations of patients with NCDs
and comorbidities that can significantly impact the outcomes of
COVID-19 patients (7, 36, 47).
Healthy dietary patterns such as the Mediterranean diet or
the DASH diet (Dietary approaches to reduce hypertension)
are characterized by high intakes of fruit and vegetables, whole
grains, fermented foods, moderate intake of fish, dairy, and low
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intake of processed foods (48, 49). Indeed, health outcomes
in relation to adherence to the Mediterranean diet during
the COVID-19 pandemic is currently under investigation
(ClinicalTrials.gov: NCT04449731). Notably, most national
dietary guidelines support these same nutritional patterns,
whereby high fruit, vegetable, nuts, dairy, and fish intake is
promoted (48). These foods are rich in bioactive compounds
with potential antithrombotic and anti-inflammatory properties
as highlighted in Table 1 (41, 60, 82–85). These include
phytochemicals such as phenolic compounds, carotenes,
alkaloids, terpenes, peptides, and bioactive lipid molecules. The
latter group of molecules includes monounsaturated fatty acids
(MUFA; e.g., oleic acid), omega-3 polyunsaturated fatty acids
(e.g., n-3 PUFA; alpha linolenic acid, eicosapentaenoic acid,
and docosahexaenoic acid), lipid soluble vitamins (vitamin D
and vitamin E), and bioactive polar lipids (e.g., phospholipids,
sphingolipids, and glycolipids) (48). Many of these compounds
exhibit potent inhibition or modulation of several signaling
pathways of key pro-inflammatory and prothrombotic mediators
such as platelet-activating factor (PAF), thrombin, collagen, ADP,
arachidonic acid, and related eicosanoids (41, 50, 60).
Dietary polar lipids found in a variety of foods (Table 1)
are of particular interest as they exhibit potent in vitro and in
vivo anti-PAF effects, which can reduce PAF-induced activation
platelets and other cells including leukocytes and endothelial
cells. Indeed, there is also evidence that polar lipids can reduce
the activities of PAF anabolic enzymes and in increase the
levels of PAF catabolic enzymes, which leads to a reduction
in the overall levels of PAF. Along with modulating PAF
metabolism, these molecules may also reduce the oxidation of
plasma lipoproteins, thus avoiding a PAF-related cascade of
synthesis and expression of other chemokines, cytokines, and




Main dietary sources Some of the documented antiplatelet effects Further reading
Bioactive lipids compounds
- Polar Lipids - Fish and seafood
- Dairy
- Olives and olive oil
- Tea
- Meat
- Wine and fermented beverages
- Reduction of PAF-induced platelet aggregation in
vitro, in vivo, and ex vivo
- Potential anti-inflammatory effects
- Affects PAF metabolism in vitro, in vivo, and ex
vivo
- Reduction of thrombin, ADP, and
collagen-induced platelet aggregation in vitro
(41, 50–59)
- n-3 PUFA - Fish and seafood
- Nuts and seeds
- Plant oils
- Reduced thrombin formation





- Vitamin E - Plant-derived oils (e.g., olive oil),
nuts, and seeds
- Reduction of PAF, ADP, thrombin, and
collagen-induced platelet aggregation in PRP and
whole blood in vitro and ex vivo
- Reduction of PAF and prostaglandin synthesis
(66–69)
- Vitamin D - Dairy
- Oily fish
- Meat
- Reduction of PAF platelet aggregation and
metabolism in vitro and in vivo
- Anti-inflammatory
- Low vitamin D associated with higher platelet
reactivity in diabetics
(70, 71)




- Inhibition of COX-1
- Inhibition of type-III collagen-induced aggregation
- Binding to glycoprotein IIb/IIIa
- Interactions with fibrinogen and its receptor.
- Reduction of thrombin formation
- Reduction of ADP-induced platelet aggregation
- Anti-inflammatory
(72–75)








- Fruit and berries
- Vegetables





- Reduction of platelet aggregation
- Anti-inflammatory effects
- Affects PAF metabolism in vitro, in vivo, and ex
vivo
- Reduction of tissue factor synthesis
- Regulation of endothelial function
- Inhibition of COX and LOX pathways
(41, 54, 76–81)
ADP, adenosine diphosphate, COX-1, cyclooxygenase-1; Lp-PLA2, lipoprotein-associated phospholipase A2; PAF, platelet-activating factor; PRP, platelet-rich plasma.
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their respective receptors and pathways, which are involved in
thrombosis, coagulation, and thrombo-inflammation (41, 51, 86,
87). For instance, nutritional trials involving the Mediterranean
diet have been shown to reduce the risk for NCDs by reducing
PAF activity in blood (88, 89). This is particularly interesting
as early metabolomics data indicates that there is a significant
shift in the glycerophospholipid composition of patient sera,
which are related to platelet degranulation and may be related
to PAF-like lipids (25). Other lipids such as n-3 PUFA are also
known to exhibit antithrombotic, anti-inflammatory, and pro-
resolving effects that may be beneficial against SARS-CoV-2
(7, 90). However, their bioavailability and efficacy is subject to
debate (61). Further clinical trials are required to determine if n-
3 PUFA and anti-PAF compounds have a functional consequence
against thrombotic complication in acute infections.
Food-derived bioactive peptides are also functionally
important as they exhibit antihypertensive, antioxidant,
antithrombotic, anti-inflammatory properties, and
immunomodulatory properties (72). Bioactive peptides found in
protein hydrolysates generally contain 2–20 amino acid residues
(91). They have a low molecular weight, high bioavailability,
and their molecular structures allows them to readily interact
with different proteins and their receptors (72). Bioactive
peptides from foods such as dairy products, seafood, seaweeds,
nuts, cereals, and other natural sources possess antithrombotic
properties that may be useful as antiplatelet agents as they seem
to interact with multiple platelet activation pathways. These
include inhibition of cyclooxygenase-1 (COX-1), inhibition of
type-III collagen-induced aggregation, binding to glycoprotein
IIb/IIIa, interacting with fibrinogen and its receptor, and
affecting thrombin (73, 74).
Other food constituents such as phenolic compounds found
in fruit, vegetables, cereals, and fermented beverages such
as wine and beer also beneficially affect platelet function
as outlined in Table 1. Indeed, resveratrol is thought to be
one of the main bioactive components of wine responsible
for its antiplatelet effects (92, 93), which is currently under
investigation as a prophylactic and therapeutic in COVID-
19 patients (ClinicalTrials.gov: NCT04400890). Herbal phenolic
compounds in conjunction with colchicine is also being
investigated for potential anti-inflammatory effects in COVID-
19 patients (ClinicalTrials.gov: NCT04392141). However, while
many of the molecules described in this review are under
investigation for their prophylactic and therapeutic properties
against SARS-CoV-2, none of the outcomes measured relate to
thrombosis yet.
Generally, only a limited number of food-derived compounds
have been investigated for their antiplatelet effects clinically as
of yet, whereby fish oils are synonymous. However, there has
been some success in developing antiplatelet nutraceuticals. One
such product is a water-soluble tomato-based nutraceutical given
the trademarked name Fruitflow R©. Fruitflow is now recognized
as a functional product by the European Food Safety Authority
(EFSA) with a recognized health claim that states that Fruitflow R©
“helps maintain normal platelet aggregation, which contributes
to healthy blood flow” (94). A 3 g dose (containing 65mg of
antiplatelet components) of Fruitflow R© recently demonstrated
antiplatelet effects that were approximately one-third the effect
of 75mg of aspirin in a double-blinded randomized clinical trial
of 47 healthy subjects (95). Nutraceuticals such as thesemay serve
as a safe antiplatelet prophylactic treatment for those at high risk
of COVID-19 who may also be at increased risk of thrombotic
complications and an alternative to pharmacological compounds
that may cause greater risk of bleeding (19).
In Table 1, there are several bioactive lipids, peptides,
phytochemicals, and phenolic compounds that can affect platelet
activity that may have the capacity to prevent the negative
thrombotic outcomes of COVID-19.While these constituents are
not the panacea to treat COVID-19, the adoption of a healthy diet
characterized by many of these molecules along with a healthy
lifestyle may help maintain hemostasis and prevent thrombotic
complications. While research is on-going to find an effective
pharmacological treatment for COVID-19, it is important to
consider that the nutritional status of a patient may affect
their health outcomes. Indeed, future COVID-19 studies must
consider the effect of nutrition on factors relating to thrombosis
and inflammation and how might nutrition play a role in the
mitigation of potential vascular and thrombotic complications.
Nutritional strategies and the use of nutraceuticals must be
further investigated for their potential to prevent thrombotic
complications in COVID-19 patients. Clinical trialists currently
investigating some of the compounds mentioned in Table 1
in conjunction with various therapies for other COVID-19
targets should consider the inclusion of measurable thrombosis-
related parameters within their existing or planned trials. While
there is no evidence that consuming nutritional supplements
might protect anyone from becoming infected with COVID-
19 or preventing its thrombotic complications, it is imperative
that national health authorities promote a healthy diet and
lifestyle to maintains one’s nutritional status and wellbeing as the
pandemic evolves.
CONCLUSIONS
It is evident that thrombotic complications are a significant
risk factor for COVID-19 patients. Therefore, there is an
urgent need to establish further clinical trials to investigate
potential pharmacological and nutritional mitigation strategies
to prevent thrombotic complications as a result of severe
COVID-19 infection. It is also important to discern whether
prophylactic antiplatelet therapies are appropriate in the case
of initially mild infections or those with comorbidities and
NCDs to prevent potential thrombosis leading to stroke or other
major complications. Indeed, it is important that clinical trialists
currently investigating some of the compounds mentioned
in Table 1 for other COVID-19 targets include measurable
thrombosis-related parameters within their existing or planned
trials. While, some institutes have endorsed guidelines for
antithrombotic and antiplatelet strategies, these have yet to be
verified as effective by clinical study. For those non-infected and
especially for those with or at increased risk of underlying NCDs,
the adoption of a healthy diet and lifestyle may prevent the
onset of severe thrombotic complications due to the presence of
bioactive compounds with antiplatelet effects. Coupling a healthy
diet and lifestyle along with preventing infection by following
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social distance guidelines, wearing a mask, and adopting good
public hygiene with prevent the onset of severe infection.
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